15. Bristol-Myers Squibb

Bristol-Myers
When Bristol-Myers unveiled its 17% revenue growth for 2016 in January, its also cut its 2017 earnings guidance.

15. Bristol-Myers Squibb
Headquarters: New York City
2016 revenues: $19.427 billion
2015 revenues: $16.56 billion

By the numbers, Bristol-Myers Squibb had the kind of year that its Big Pharma rivals would have liked. Fueled by some recent launches—including the immuno-oncology blockbuster Opdivo—the company grew sales by a whopping 17%. That’s not easy to do when your baseline is more than $16 billion.

And the numbers don’t lie. Bristol-Myers managed to weather its first full year without U.S. revenue from Abilify and Erbitux, whose commercial rights went back to BMS partner Otsuka in mid-2015. Competition for antivirals Baraclude, Reyataz and Sustiva all took $100 million-plus bites out of those meds; BMS handled that, too.

 Why? A few meds chipped in low-end, double-digit growth: the anti-inflammatory Orencia, up 20% to $2.265 billion, and the leukemia treatment Sprycel, up 13% to  $1.824 billion. Empliciti, a brand-new multiple myeloma med, jumped from $3 million to $150 million.

But two other meds stole the show. Opdivo, the immuno-oncology therapy, zoomed to $3.774 billion after pulling in $942 million in 2015. And Eliquis, an anticoagulant partnered with Pfizer, took an 80% leap to $3.343 billion—results would have wowed a crowd if they weren’t outshone by Opdivo.

And therein lies the problem for Bristol-Myers. Opdivo isn’t expected to take such a big leap in 2017, partly because it fell short in an important lung cancer trial that could have opened up a big new market—previously untreated patients—and cement its position as leader in the I/O market. The news of Opdivo’s failure in that trial, known as Checkmate-026, sent Bristol-Myers’ shares reeling. The company lost more than $35 billion off its market cap.

With that new indication sidelined, Opdivo stands to lose share in second-line lung cancer, too, some analysts say, as Merck & Co.’s Keytruda becomes a more formidable competitor.

Opdivo also won’t zoom into early lung cancer with companion drug Yervoy by its side. After the Opdivo trial failure news hit in August, Bristol-Myers announced in early January 2017 that it wouldn’t try to win accelerated approval for that combo.

Bristol-Myers is still plugging away with Opdivo in indications beyond lung cancer. It won a head and neck cancer approval in late 2016, for instance, And BMS is confident that the drug can succeed in combination cancer trials; it has multiple development partnerships testing multiple cocktails in multiple cancers, including one struck in February with Exelexis for a test in first-line kidney cancer.

Still, for now, Opdivo’s fortunes aren’t as sure as they once were. When Bristol-Myers unveiled its 17% revenue growth for 2016 in January, its also cut its 2017 earnings guidance. It’s looking for sales growth in the low-single digits and earnings per share of $2.70 to $2.90, down from $2.85-$3.05. Its shares plummeted again, to $46.82, though they’ve since recovered to $57.26 as of press time.

Now, the company faces pressure from activist investors, one of which pushed BMS to add three directors to its board. The second is Carl Icahn, who has a history of pushing deals and concessions in the biopharma industry. That, in turn, has market-watchers gossiping about a potential megamerger pairing Bristol-Myers with a fellow Big Pharma or even, perhaps, a Big Biotech.

Clearly 2016 was a roller-coaster ride for Bristol-Myers, with a sickening drop in late summer. But at least it had a nice upward ride before the fall.

15. Bristol-Myers Squibb

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.